Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000542048 | SCV000652086 | pathogenic | Focal segmental glomerulosclerosis 5; Charcot-Marie-Tooth disease dominant intermediate E | 2020-08-07 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has been observed in individual(s) with clinical features of INF2-related conditions (PMID: 31937884, Invitae). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 472842). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with valine at codon 73 of the INF2 protein (p.Gly73Val). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and valine. |
Gene |
RCV004721436 | SCV005328245 | likely pathogenic | not provided | 2024-03-11 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 31937884, 37491439, 22965130, Fujii2023[casereport], 23014460, 31096240) |